Shire's Vyvanse performs well in BED
This article was originally published in Scrip
Shire's shares opened up 2% on 5 November at £28.77 on the London Stock Exchange following positive top-line Phase III results for its approved ADHD drug Vyvanse (lisdexamfetamine dimesylate) in binge eating disorder (BED). The company said it would file for US approval in the new indication by the third quarter of 2014 on the back of the new data, which came earlier than expected.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.